5 insights for executives
A new prescription for market success
What’s the bottom line?
In the rapidly evolving market landscape we call Pharma 3.0, pharmaceutical companies must develop new ways of gaining market share.
Companies must focus on being part of the right outcome for patients.
They must become commercially agile — able to move quickly to bring the right resources to bear at the right time.
To survive and to thrive, leading companies are embracing the outcome-based model and adapting their sales, marketing and operations resources accordingly. Companies that do not are likely to find themselves disconnected from the market, with their ability to influence their own success diminished and their very survival possibly at stake.